Anna Skaya Leaves Pet Genetics Behind to Launch a New Venture in Miami

From Pet DNA to a Broader Platform

Anna Skaya, the entrepreneur best known for founding Basepaws — the consumer DNA testing company that brought genomic insights to pet owners and helped veterinary medicine take a meaningful step toward precision care — is now channeling that experience into something new. Having built and established herself in the pet genetics space, Skaya has relocated to Miami and is making dual moves: investing in early-stage pet-focused startups and constructing an entirely new venture of her own. The pivot is a notable signal from one of the genomics industry's more entrepreneurially minded figures, suggesting that the skills honed in consumer genetic testing translate directly into broader platform-building and venture creation.

Why This Matters for Genomics Entrepreneurs

Skaya's trajectory is worth examining closely by genomics professionals because it illustrates a maturing pattern in the industry. Consumer DNA testing — whether for humans or animals — requires founders to master a uniquely demanding combination of laboratory science, regulatory navigation, direct-to-consumer marketing, and data management. Those capabilities, once developed, do not stay neatly confined to a single species or application. Skaya's decision to now fund other pet startups suggests she sees continued whitespace in the animal health and genomics market, even as the space has grown more competitive. Her choice to simultaneously build something new, rather than simply transition into a pure investor role, underscores a belief that founder-led creation still holds advantages over capital deployment alone. Miami's growing reputation as a hub for technology entrepreneurship provides the ecosystem infrastructure — access to venture capital networks, talent, and cross-industry collaboration — that a genomics-adjacent founder needs when stepping beyond a single-category company.

What's Next for Pet Genomics and Beyond

The pet genomics sector Skaya helped pioneer has expanded considerably since the early days of companion animal DNA testing. Veterinary genomics now intersects with pharmacogenomics, hereditary disease screening, and microbiome analysis, creating multiple layers of commercial opportunity that did not exist a decade ago. By positioning herself as both an investor and an active builder within Miami's startup scene, Skaya is effectively placing a bet that the next wave of innovation in this space will come from founders who understand genomic data at a product level, not just a scientific one. Her new venture's details remain closely held for now, but its existence points to continued momentum at the intersection of consumer genomics, animal health, and technology entrepreneurship.

For the genetic testing industry broadly, Skaya's story reinforces a compelling thesis: genomics founders who build once are increasingly building again, and the domain expertise they carry is becoming a durable form of venture capital in its own right.